These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1808124)

  • 1. Blood-pool enhancement with SH U 508 A. Results of phase II clinical trials.
    Schlief R; Schürmann R; Niendorf HP
    Invest Radiol; 1991 Nov; 26 Suppl 1():S188-9; discussion S198-200. PubMed ID: 1808124
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and tolerability of iodixanol. A dimeric, nonionic contrast medium: an emphasis on European clinical phases I and II.
    Bolstad B; Borch KW; Grynne BH; Lundby B; Nossen JO; Kloster YF; Kristoffersen DT; Andrew E
    Invest Radiol; 1991 Nov; 26 Suppl 1():S201-4; discussion S208. PubMed ID: 1808130
    [No Abstract]   [Full Text] [Related]  

  • 3. [SH/TA-508 clinical phase II study: dose evaluation of SH/TA-508 in echocardiography].
    Miyatake K; Yamaguchi T; Takatsuji H; Igarashi T; Nakamura K; Saeki F; Kato K; Suzuki M; Kamada T; Yamamoto K
    J Cardiol; 1995 Aug; 26(2):111-33. PubMed ID: 7674143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ioxilan. Initial clinical observations.
    Callantine MR; Sovak M; Lu HP
    Invest Radiol; 1990 Sep; 25 Suppl 1():S107-8. PubMed ID: 2283219
    [No Abstract]   [Full Text] [Related]  

  • 5. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients.
    Rummeny E; Ehrenheim C; Gehl HB; Hamm B; Laniado M; Lodemann KP; Schmiedel E; Steudel A; Vogl TG
    Invest Radiol; 1991 Nov; 26 Suppl 1():S142-5; discussion S150-5. PubMed ID: 1808111
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological evaluation of the new stable ultrasound contrast agent LK565: a phase one clinical trial.
    Funke B; Maerz HK; Okorokow S; Polata S; Lehmann I; Sack U; Wild P; Geisler T; Zotz RJ
    Cardiovasc Ultrasound; 2004 Sep; 2():16. PubMed ID: 15357870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two blood pool contrast agents for 0.5-T MR angiography: experimental study in rabbits.
    Clarke SE; Weinmann HJ; Dai E; Lucas AR; Rutt BK
    Radiology; 2000 Mar; 214(3):787-94. PubMed ID: 10715047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial program for iopentol. A new nonionic ratio 3.0 contrast medium with emphasis on clinical phases I and II.
    Andrew E; Waaler A; Jakobsen J; Holager T; Lambrechts M; Moxnes A; Kruger Hagen E; Bach-Gansmo T
    Invest Radiol; 1988 Sep; 23 Suppl 1():S189-92. PubMed ID: 3058629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrast-enhanced transcranial color-coded sonography in acute cerebral infarction.
    Cheung RT
    Stroke; 2000 Aug; 31(8):2025-6. PubMed ID: 10926974
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
    VanWagoner M; O'Toole M; Worah D; Leese PT; Quay SC
    Invest Radiol; 1991 Nov; 26(11):980-6. PubMed ID: 1743922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse reactions to intravenous contrast media in routine clinical practice.
    Wolf GL; Silvay-Mandeau O
    Invest Radiol; 1990 Sep; 25 Suppl 1():S20-1. PubMed ID: 2283244
    [No Abstract]   [Full Text] [Related]  

  • 12. [Methodological aspects of contrast echocardiography].
    Zaretskiĭ VV; Bobkov VV; Gotman LN; Evelev VA; Babalian GV
    Kardiologiia; 1980 Mar; 20(3):32-5. PubMed ID: 7373986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and biological study of the immediate adverse reactions after the intravenous administration of organoiodate contrast substances. I. A clinico-statistical analysis].
    Păsculescu G; Dorca N; Baciu Z; Popa Luca I; Mihăilas R; Constantinescu D
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1985; 37(1):75-8. PubMed ID: 2861640
    [No Abstract]   [Full Text] [Related]  

  • 14. Contrast-enhanced transcranial color-coded real-time sonography. Results of a phase-two study.
    Bogdahn U; Becker G; Schlief R; Reddig J; Hassel W
    Stroke; 1993 May; 24(5):676-84. PubMed ID: 8488522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, prospective, open label, randomized, controlled phase IIIb study of SH U 508 a (Levovist) for Doppler signal enhancement in the portal vascular system.
    Gebel M; Caselitz M; Bowen-Davies PE; Weber S
    Ultraschall Med; 1998 Aug; 19(4):148-56. PubMed ID: 9816618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials.
    Patten RM; Lo SK; Phillips JJ; Bowman SC; Glazer GM; Wall SD; Bova JG; Harris RD; Wheat RL; Johnson CD
    Radiology; 1993 Oct; 189(1):277-83. PubMed ID: 8372205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled clinical trial.
    Niendorf HP; Haustein J; Louton T; Beck W; Laniado M
    Invest Radiol; 1991 Nov; 26 Suppl 1():S221-3; discussion S232-5. PubMed ID: 1808134
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ionic and non-ionic contrast media].
    Bryc S
    Ann Univ Mariae Curie Sklodowska Med; 1986; 41():145-56. PubMed ID: 3154050
    [No Abstract]   [Full Text] [Related]  

  • 19. Anaphylacti shock after intravenous galactose.
    Rud C
    Lancet; 1968 Nov; 2(7579):1189. PubMed ID: 4176968
    [No Abstract]   [Full Text] [Related]  

  • 20. [Improved reproducibility of contrast echocardiography by SH U 454. Experimental studies using digital subtraction echocardiography].
    Grube E; Fritzsch T
    Z Kardiol; 1986 Jun; 75(6):355-62. PubMed ID: 3529670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.